Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations

被引：0
|
作者：
Mueller, Martin C. [1 ]
Cortes, Jorge [2 ]
Kim, Dong-Wook [3 ]
Druker, Brian J. [4 ]
Erben, Philipp [1 ]
Pasquini, Ricardo [5 ]
Hughes, Timothy P. [6 ]
Matloub, Yousif [7 ]
Ploughman, Lynn [7 ]
Hochhaus, Andreas [1 ]
机构：
[1] Univ Heidelberg, Med Fak Mannheim, D-6800 Mannheim, Germany
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] St Marys Hosp, Div Hematol, Seoul, South Korea
[4] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA
[5] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil
[6] Inst Med & Vet Sci, Adelaide, SA 5000, Australia
[7] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [31] IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
    Tiribelli, M.
    Latagliata, R.
    Breccia, M.
    Luciano, L.
    Castagnetti, F.
    Gozzini, A.
    Cambrin, G. Rege
    Annunziata, M.
    Stagno, F.
    Pregno, P.
    Albano, F.
    Abruzzese, F.
    Musto, P.
    Sora, F.
    Ferrero, D.
    Montefusco, E.
    Cavazzini, F.
    Binotto, G.
    Fanin, R.
    Pane, F.
    Rosti, G.
    Santini, V.
    Fava, C.
    Alimena, G.
    Vigneri, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 347 - 347
  • [32] Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia
    Tiribelli, Mario
    Latagliata, Roberto
    Luciano, Luigiana
    Castagnetti, Fausto
    Gozzini, Antonella
    Cambrin, Giovanna Rege
    Annunziata, Mario
    Stagno, Fabio
    Pregno, Patrizia
    Albano, Francesco
    Abruzzese, Elisabetta
    Musto, Pellegrino
    Montefusco, Enrico
    Fava, Carmen
    Fanin, Renato
    Pane, Fabrizio
    Rosti, Gianantonio
    Breccia, Massimo
    Alimena, Giuliana
    Vigneri, Paolo
    ANNALS OF HEMATOLOGY, 2013, 92 (02) : 179 - 183
  • [33] Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia
    Mario Tiribelli
    Roberto Latagliata
    Luigiana Luciano
    Fausto Castagnetti
    Antonella Gozzini
    Giovanna Rege Cambrin
    Mario Annunziata
    Fabio Stagno
    Patrizia Pregno
    Francesco Albano
    Elisabetta Abruzzese
    Pellegrino Musto
    Enrico Montefusco
    Carmen Fava
    Renato Fanin
    Fabrizio Pane
    Gianantonio Rosti
    Massimo Breccia
    Giuliana Alimena
    Paolo Vigneri
    Annals of Hematology, 2013, 92 : 179 - 183
  • [34] BCR-ABL independent gene mutations in patients with chronic myeloid leukemia
    Schmidt, M.
    Rinke, J.
    Schaefer, V.
    Ziermann, J.
    Eigendorff, E.
    Hochhaus, A.
    Ernst, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 210 - 210
  • [35] Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
    Hughes, Timothy
    Saglio, Giuseppe
    Branford, Susan
    Soverini, Simona
    Kim, Dong-Wook
    Mueller, Martin C.
    Martinelli, Giovanni
    Cortes, Jorge
    Beppu, Lan
    Gottardi, Enrico
    Kim, Dongho
    Erben, Philipp
    Shou, Yaping
    Haque, Ariful
    Gallagher, Neil
    Radich, Jerald
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4204 - 4210
  • [36] Detection of BCR-ABL point mutations in patients with chronic myeloid leukemia (CML) resistant to imatinib.
    Silveira, Rosana A.
    Albuquerque, Dulcineia M.
    Assis, Angela M.
    Ichihara, Edson
    de Souza, Carmino A.
    Costa, Fernando F.
    Delamain, Marcia T.
    Vigorito, Afonso C.
    Lorand-Metze, Irene
    Miranda, Eliana
    Pagnano, Katia B. B.
    BLOOD, 2006, 108 (11) : 289B - 289B
  • [37] Modelling BCR-ABL1 Dynamics in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) during Frontline Therapy with High-Dose Imatinib, Nilotinib, or Dasatinib
    Olshen, Adam
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    Gonen, Mithat
    Michor, Franziska
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1113 - 1113
  • [38] Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP)
    Atallah, E. L.
    Kantarjian, H.
    O'Brien, S.
    Jones, D.
    Borthakur, G.
    Nicaise, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Dasatinib (SPRYCEL®) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP).
    Cortes, Jorge
    O'Brien, S.
    Jones, D.
    Borthakur, G.
    Giles, F.
    Nicaise, C.
    Kantarjian, H. M.
    BLOOD, 2006, 108 (11) : 613A - 613A
  • [40] Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Jain, Preetesh
    Kantarjian, Hagop M.
    Jabbour, Elias
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Gachimova, Evguenia
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
12345